Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.58 |
| ▸ | TSHR | P16473 | 2/20 | 0.50 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.50 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ERCC5 | P28715 | 1/20 | 0.44 |
| ▸ | FEN1 | P39748 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3280428 | 0.86 | TP53 (0.50) | KMT2ATSHRHPGDMEN1SMN1; SMN2 | |
| SCHEMBL30037151 | 0.84 | KMT2A (0.59) | KMT2ATSHRMAPK1HPGDERCC5 | |
| SCHEMBL354228 | 0.84 | KMT2A (0.59) | KMT2ATSHRMAPK1HPGDERCC5 | |
| SCHEMBL11216342 | 0.84 | KMT2A (0.59) | KMT2ATSHRMAPK1HPGDERCC5 | |
| Hydrochloric Acid SCHEMBL1776796 | 0.83 | KMT2A (0.58) | KMT2ATSHRMAPK1HPGDERCC5 | |
| SCHEMBL28873372 | 0.81 | KMT2A (0.51) | KMT2ATSHRMAPK1HPGDERCC5 | |
| SCHEMBL6832097 | 0.81 | KMT2A (0.56) | KMT2ATSHRMAPK1HPGDERCC5 | |
| Hydrochloric Acid SCHEMBL11560303 | 0.79 | KMT2A (0.54) | KMT2ATSHRMAPK1HPGDERCC5 | |
| SCHEMBL11879792 | 0.79 | KMT2A (0.64) | KMT2ATSHRMAPK1HPGDERCC5 | |
| SCHEMBL1436159 | 0.78 | KDM4E (0.52) | KMT2ATSHRMAPK1HPGDMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3760619-A1 | SATURATED RING-CONDENSED DIHYDROPYRIMIDINONE OR DIHYDROTRIAZINONE COMPOUND, AND PHARMACEUTICAL USE THEREOF | Japan Tobacco Inc. (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-7906540-B2 | Antivirals for HIV and AIDS; compounds are 2-1,2,4-triazolin-5-ones, substituted with aryl(oxy)methyl or benzylamino at position 3; use in combination with antivirals; treating drug resistance infections | ROCHE PALO ALTO LLC (US) | 2011-03-15 | — | — | US | disclosed |
| EP-2142520-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2010-01-13 | — | — | EP | disclosed |
| EP-2134711-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. Hoffmann-Roche AG (CH) | 2009-12-23 | — | — | EP | disclosed |
| US-20080293664-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-11-27 | — | — | US | disclosed |
| WO-2008122534-A2 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-16 | — | — | WO | disclosed |
| WO-2008119662-A1 | NON-NUCLEOSIDE REVERSE TRANSCRIPTASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2008-10-09 | — | — | WO | disclosed |
| US-20080249151-A1 | Non-nucleoside reverse transcriptase inhibitors | ROCHE PALO ALTO LLC | 2008-10-09 | — | — | US | disclosed |
| US-6632833-B1 | Their preparation and to their use as pesticides | BAYER AKTIENGESELLSCHAFT (DE) | 2003-10-14 | — | — | US | disclosed |
| EP-1306371-A1 | Cyclic imines | Bayer CropScience AG (DE) | 2003-05-02 | — | — | EP | disclosed |
| EP-0942901-B1 | CYCLIC IMINES AS PESTICIDES | BAYER CROPSCIENCE AG (DE) | 2003-03-05 | — | — | EP | disclosed |
| EP-0942901-A1 | CYCLIC IMINES AS PESTICIDES | BAYER AG (DE) | 1999-09-22 | — | — | EP | disclosed |
| WO-1998022438-A1 | CYCLIC IMINES AS PESTICIDES | BAYER AKTIENGESELLSCHAFT (DE) | 1998-05-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080293664-A1 | Non-nucleoside reverse transcriptase inhibitors | XDH, REV1, RTF1 | KMT2A 1859/4885TSHR 1684/4885MAPK1 1864/4885 |
| US-20080249151-A1 | Non-nucleoside reverse transcriptase inhibitors | QTRT1, RTF1, REV1 | KMT2A 1583/4885TSHR 1975/4885MAPK1 2076/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.